# FDA Approves Accord Healthcare's Generic Fluorouracil Injection Accord Healthcare, Inc. has received FDA approval for its generic intravenous fluorouracil formulation (ANDA040798), expanding the competitive landscape in the oncology market and potentially reducing costs for hospitals and cancer treatment centers relying on this established chemotherapy agent. The approval allows Accord to compete directly with branded versions, likely increasing pricing pressure while improving patient access to this widely-used cancer medication across multiple indications.